Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 (HARMONY)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Germany,Austria,Germany,Germany,Germany,Germany,Germany,Spain,Italy,Italy,Italy,Germany,Spain,Germany,Germany,Spain,Spain,Spain,Slovenia,Finland,Switzerland,Switzerland,Switzerland,Belgium,Belgium,Belgium,Belgium,France,France,France,Czechia,Netherlands,United States,Netherlands,Netherlands,Netherlands,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom
Call: Development of an outcomes-focused data platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies (H2020-JTI-IMI2-2015-06-two-stage, 2015)
Start date: 2017-01-01
End date: 2023-06-30
Duration (months): 78.0
Total project cost (EUR): 42433075.15
EU funding (EUR): 20200000.0
Participants: 59
Project status: SIGNED

Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in quality of life, many children and adults with HMs still die from these disorders or experience disabling complications. Therefore, improvement of health care of HMs is an unmet medical need. Thus, it is important to define and align standard and efficient sets of HMs outcomes to measure and evaluate HM data for clinical decisions, long term risk/benefit profile, reimbursement, value analysis, and clinical trials design. Improving outcome measures and endpoint definitions by taking into account “real-life” data and differences in cross-national healthcare practice will undoubtedly result in an optimized, sustainable and effective treatment delivery, as well as in desirable and innovative accelerated pathways for novel drug availability. All these challenges will be addressed within a pan-EU perspective by HARMONY (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY), a comprehensive public-private European consortium of excellence. HARMONY consortium is made up of 51 partners: 44 participants from 10 European countries and 7 pharmaceutical companies from the EFPIA. HARMONY aims to assemble, assess, connect, and analyze heterogeneous HM patient derived Big Data sets to define sets of outcome indicators that can be used for decision-making by key healthcare stakeholders. The consortium will orchestrate leading experts and working cooperative groups in HMs, European study alliances, pharmaceutical market leaders, patient advocacy groups, HTA and regulatory agencies, to: (i) optimize Europe-wide data collection and create a high-quality HM data repository for further explorative studies; (ii) establish a clinical data-sharing platform that empowers clinicians, patients and policy stakeholders to improve decision-making procedures and identify appropriate treatments to patients with HMs

Keywords: hematological malignancy,leukemia,lymphoma,myelodysplastic syndromes,multiple myeloma,childhood cancer,real life patient data,big data platform,outcome measures